

MPS VI Selected Publications

Disease and Diagnosis	Wood T, Bodamer OA, Burin MG, et al. Expert recommendations for the laboratory diagnosis of MPS VI. <i>Mol Genet Metab.</i> 2012;106(1):73-82. DOI: 10.1016/j.ymgme.2012.02.005 ^a
	Swiedler SJ, Beck M, Bajbouj M, et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). <i>Am J Med Genet A.</i> 2005;134A(2):144-150. DOI: 10.1002/ajmg.a.30579 ^a
Galsulfase	Burton BK, Harmatz PR, Horvathova V, et al. Long-term enzyme replacement therapy: Findings from the mucopolysaccharidosis VI clinical surveillance program after 15 years follow-up. <i>Mol Genet Metab.</i> 2025;145(3):109135. DOI: 10.1016/j.ymgme.2025.109135
	Garcia P, Phillips D, Johnson J, et al. Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy. <i>Mol Genet Metab.</i> 2021;133(1):100-108. DOI: 10.1016/j.ymgme.2021.03.006
	Horovitz DDG, Leao EKEA, Ribeiro EM, et al. Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study. <i>Mol Genet Metab.</i> 2021;133(1):94-99. DOI: 10.1016/j.ymgme.2021.02.006
	Harmatz PR, Lampe C, Parini R, et al. Enzyme replacement therapy outcomes across the disease spectrum: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program. <i>J Inherit Metab Dis.</i> 2019;42(3):519-526. DOI: 10.1002/jimd.12079
	Lampe C, Harmatz PR, Parini R, et al. Enzyme replacement therapy initiated in adulthood: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program. <i>Mol Genet Metab.</i> 2019;127(4):355-360. DOI: 10.1016/j.ymgme.2019.06.008
	Quartel A, Harmatz PR, Lampe C, et al. Long-term galsulfase treatment associated with improved survival of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): 15-year follow-up from the survey study. <i>J Inborn Errors Metab Screen.</i> 2018;6:1–6. DOI: 10.1177/2326409818755800
	Harmatz P, Hendriksz CJ, Lampe C, et al. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). <i>Mol Genet Metab.</i> 2017;122(1–2):107–112. DOI: 10.1016/j.ymgme.2017.03.008
	Harmatz PR, Garcia P, Guffon N, et al. Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI. <i>J Inherit Metab Dis.</i> 2014;37(2):277–287. DOI: 10.1007/s10545-013-9654-7
Management Guidelines	Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. <i>J Pediatr.</i> 2006;148(4):533-539. DOI: 10.1016/j.jpeds.2005.12.014 ^a
	Akyol MU, Alden TD, Amartino H, et al. Recommendations for the management of MPS VI: Systematic evidence- and consensus-based guidance. <i>Orphanet J Rare Dis.</i> 2019;14(1):118. DOI: 10.1186/s13023-019-1080-y

^aNot Open Access. Available upon Request

If you would like a copy of any publication, please contact us at medinfo@bmrn.com or through our [web request form](#)